Glenmede Trust Co. NA cut its holdings in Exelon Co. (NASDAQ:EXC – Free Report) by 8.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 592,557 shares of the company’s stock after selling 52,390 shares during the period. Glenmede Trust Co. NA owned 0.06% of Exelon worth $24,028,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Exelon by 1.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,390,685 shares of the company’s stock valued at $52,249,000 after acquiring an additional 16,661 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its holdings in shares of Exelon by 10.3% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 22,248 shares of the company’s stock worth $841,000 after purchasing an additional 2,075 shares during the period. Tidal Investments LLC increased its position in shares of Exelon by 97.1% during the 1st quarter. Tidal Investments LLC now owns 69,268 shares of the company’s stock valued at $2,602,000 after purchasing an additional 34,132 shares during the last quarter. Virtu Financial LLC purchased a new stake in Exelon during the 1st quarter valued at $252,000. Finally, Swedbank AB bought a new stake in Exelon in the first quarter worth $96,859,000. 80.92% of the stock is owned by hedge funds and other institutional investors.
Exelon Trading Up 0.1 %
NASDAQ:EXC opened at $39.51 on Thursday. The firm has a 50-day simple moving average of $39.60 and a 200-day simple moving average of $37.86. Exelon Co. has a one year low of $33.35 and a one year high of $41.42. The firm has a market cap of $39.70 billion, a P/E ratio of 16.26, a P/E/G ratio of 2.79 and a beta of 0.54. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.97 and a current ratio of 1.09.
Exelon Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Monday, November 11th will be issued a $0.38 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.52 dividend on an annualized basis and a yield of 3.85%. Exelon’s dividend payout ratio is presently 62.55%.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on EXC shares. Barclays increased their target price on shares of Exelon from $41.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Wells Fargo & Company increased their price objective on shares of Exelon from $40.00 to $42.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. Morgan Stanley dropped their target price on Exelon from $46.00 to $44.00 and set an “equal weight” rating for the company in a research report on Friday, November 22nd. Scotiabank increased their price target on Exelon from $37.00 to $40.00 and gave the stock a “sector perform” rating in a report on Tuesday, August 20th. Finally, UBS Group boosted their price objective on Exelon from $40.00 to $43.00 and gave the company a “neutral” rating in a report on Friday, September 20th. Eleven analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Exelon has a consensus rating of “Hold” and an average price target of $41.25.
View Our Latest Analysis on EXC
About Exelon
Exelon Corporation, a utility services holding company, engages in the energy distribution and transmission businesses in the United States and Canada. The company is involved in the purchase and regulated retail sale of electricity and natural gas, transmission and distribution of electricity, and distribution of natural gas to retail customers.
Further Reading
- Five stocks we like better than Exelon
- Roth IRA Calculator: Calculate Your Potential Returns
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Insider Buying Explained: What Investors Need to Know
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- 3 Best Fintech Stocks for a Portfolio Boost
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Exelon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelon and related companies with MarketBeat.com's FREE daily email newsletter.